Screening | Topics

Reduction in Cancer Screenings During COVID-19 May Lead to More Late-Stage Disease, Poorer Outcomes
November 29, 2021

Late-stage cancer and poor outcomes for patients may occur as a result of low screening numbers during the COVID-19 pandemic.

Clinical Limit of Detection May Represent Viable cfDNA Metric For Detection of Multiple Cancers
September 19, 2021

Data from the Circulating Cell-Free Genome Atlas on Clinical limit of detection, or cLOD, may help investigators better detect multiple cancers at earlier stages.

Overcoming Barriers to Cancer Screening in Diverse LGBTQ Populations
June 28, 2021

An integrated review highlights the barriers standing between diverse LGBTQ populations and cancer screenings.

Decline in HPV-Related Cervical Cancer May Inform Screening and Vaccination Guidance for Other Tumor Types
May 20, 2021

Seventeen years of data indicate that HPV-related cervical cancer incidence is declining, but other tumors related to the virus persist.

USPSTF Lowers the Recommended Age for CRC Screenings, Mandating Insurance Coverage
May 18, 2021

Recommendations published in JAMA are set to change colorectal cancer screening guidance for all individuals in the United States.

Next-Generation Sequencing for Advanced Pancreatic Cancer: A Technology Whose Time Has NOT Come
May 15, 2021

In his "Letter to the Readers", co-editor-in-chief of the journal ONCOLOGY Howard S. Hochster, MD, reviews the utility of next-generation sequencing in pancreatic ductal adenocarcinoma.

CancerNetwork Honors World Health Day by Looking at Recent Breakthroughs in Cancer Prevention, Screening
April 07, 2021

CancerNetwork® reports on updates in prevention and earlier diagnosis of colorectal, breast, and other cancers.

Narrow Band Imaging Earns FDA Clearance for Real-Time Assessment of Colorectal Polyps With Neoplastic Potential
March 17, 2021

A novel imaging technology was cleared by the FDA to detect polyps with neoplastic potential during conduct of colonoscopy that aligns with pathological assessment with greater than 90% predictive ability.

RaDaR Assay Gets FDA Designation for Expediated Regulatory Pathway
March 10, 2021

The liquid biopsy assay RaDaR has been given a breakthrough device designation for use in the detection of minimal residual disease in early-stage cancers.

Psychological Responses to Genetic Counseling, Multigene Panel Testing Reveals Low Patients Distress, Uncertainty
February 09, 2021

Investigators suggest that results of a study may help to identify concerns of individuals undergoing panel testing and ways to support their needs.